STRO-1+ Cell Therapy for Steroid-Resistant Asthma
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for respiratory conditions such as asthma and COPD are limited in effectiveness, particularly for patients who do not respond to standard corticosteroid and bronchodilator therapies, and there is a need for new therapies that can address inflammation, airway hyperresponsiveness, and lung remodeling.
Innovation Solution
The use of STRO-1+ cell preparations, which include enriched STRO-1+ cells and their progeny or soluble factors, to reduce TH2-mediated allergic responses, eosinophil infiltration, and inflammation in the lungs, thereby addressing bronchial hyperresponsiveness and lung remodeling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If corticosteroids and beta-agonists are used to treat asthma, then airway inflammation and bronchospasm are controlled, but 5-10% of patients remain symptomatic despite treatment
Solution Approach 1:
The patent changes the therapeutic parameter from conventional corticosteroids and beta-agonists to anti-IgE therapy (omalizumab), targeting a different pathophysiological mechanism. This parameter change allows treatment of patients who do not respond to standard therapy by addressing the underlying IgE-mediated allergic response rather than just suppressing inflammation or bronchospasm symptoms
Solution Approach 2:
The patent introduces anti-IgE antibodies (omalizumab) as an intermediary that binds to free IgE, preventing IgE from binding to mast cell FcεRI receptors. This intermediary mechanism blocks the allergic cascade at its initiation point, providing therapeutic benefit for patients who remain symptomatic despite conventional anti-inflammatory and bronchodilator treatment
2Reliability
If high doses of corticosteroids are used to control severe asthma, then inflammation is suppressed, but side effects increase
Solution Approach 1:
The patent extracts and targets the specific pathogenic element (IgE) that drives allergic inflammation, rather than using broad-spectrum corticosteroids that suppress all inflammatory pathways. By removing the specific trigger (IgE-mediated activation) through anti-IgE therapy, effective inflammation control is achieved with targeted intervention, potentially reducing the need for high-dose corticosteroids and their associated side effects
Solution Approach 2:
The patent changes the therapeutic approach from non-selective anti-inflammatory suppression (corticosteroids) to selective IgE pathway blockade (omalizumab). This parameter change enables targeted control of IgE-mediated inflammation without the broad immunosuppressive effects and side effects of high-dose corticosteroid therapy
3Ease of operation
If standard therapies are used for COPD, then bronchodilation is achieved, but inflammatory cells and mediators are not sensitive to corticosteroid treatment
Solution Approach 1:
The patent segments the therapeutic approach by separating bronchodilation (achieved through beta-agonists and anticholinergics) from anti-inflammatory therapy. For COPD patients with an allergic component, anti-IgE therapy provides a segmented, targeted anti-inflammatory mechanism that does not rely on corticosteroid sensitivity, addressing the neutrophil-dominated inflammation that is resistant to conventional corticosteroid treatment
Data Source
AI summary
The present disclosure provides methods of treating or preventing respiratory condition and/or for treating an IgE-mediated allergy and/or for reducing an allergic response to an allergen and/or for inducing anergy to an allergen in a subject and/or improving lung function in a subject suffering from an allergy comprising administering to a subject a population of cells enriched for STRO-1+ cells and/or progeny thereof and/or soluble factors derived therefrom.